Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis

Yamada, Takayuki; Wakabayashi, Mako; Bhalla, Abhinav; Chopra, Nitin; Miyashita, Hirotaka; Mikami, Takahisa; Ueyama, Hiroki; Fujisaki, Tomohiro; Saigusa, Yusuke; Yamaji, Takahiro; Azushima, Kengo; Urate, Shingo; Suzuki, Toru; Abe, Eriko; Wakui, Hiromichi; Tamura, Kouichi

doi:10.1186/s12933-020-01197-z

Cardiovascular Diabetology

Table 3 The summary of sensitivity analyses

From: Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis

Sensitivity analysis	Subjects
Sensitivity analysis	SGLT-2 inhibitors	GLP-1 RAs	Comparison	Risk ratio	95% CI	I² (%)	p value
MACE-3
MACE-3 as the primary outcome	17514	10644	SGLT-2 inhibitors vs. placebo	0.87	0.76–1.00	50.4	0.033
			GLP-1 RAs vs. placebo	0.91	0.79–1.04
			SGLT-2 inhibitors vs. GLP-1 RAs	0.96	0.79–1.17
Without ELIXA	20106	14007	SGLT-2 inhibitors vs. placebo	0.85	0.75–0.97	49.5	0.037
			GLP-1 RAs vs. placebo	0.88	0.76–1.03
			SGLT-2 inhibitors vs. GLP-1 RAs	0.97	0.79–1.18
Daily GLP-1 RAs	20106	6635	SGLT-2 inhibitors vs. placebo	0.84	0.75–0.96	47.7	0.053
			GLP-1 RAs vs. placebo	0.86	0.73–1.02
			SGLT-2 inhibitors vs. GLP-1 RAs	0.99	0.80–1.21
Weekly GLP-1 RAs	20106	4009	SGLT-2 inhibitors vs. placebo	0.85	0.76–0.95	31.8	0.19
			GLP-1 RAs vs. placebo	1.01	0.83–1.22
			SGLT-2 inhibitors vs. GLP-1 RAs	0.85	0.68–1.05
GLP-1 analogues	20106	6068	SGLT-2 inhibitors vs. placebo	0.85	0.76–0.95	30.6	0.17
			GLP-1 RAs vs. placebo	0.81	0.69–0.95
			SGLT-2 inhibitors vs. GLP-1 RAs	1.05	0.86–1.27
Exendin-4 analogues	20106	4576	SGLT-2 inhibitors vs. placebo	0.85	0.77–0.94	28.7	0.21
			GLP-1 RAs vs. placebo	1.03	0.88–1.20
			SGLT-2 inhibitors vs. GLP-1 RAs	0.83	0.69–0.99
Renal outcomes
Renal endpoints as secondary outcomes	18583	7534	SGLT-2 inhibitors vs. placebo	0.67	0.55–0.83	0	0.86
			GLP-1 RAs vs. placebo	0.86	0.72–1.03
			SGLT-2 inhibitors vs. GLP-1 RAs	0.78	0.59–1.03
Macroalbuminuria	1505	7534	SGLT-2 inhibitors vs. placebo	N/A	N/A	0	0.73
			GLP-1 RAs vs. placebo	0.91	0.81–1.02
			SGLT-2 inhibitors vs. GLP-1 RAs	N/A	N/A
Weekly GLP-1 RAs	20088	5376	SGLT-2 inhibitors vs. placebo	0.65	0.55–0.78	0	0.73
			GLP-1 RAs vs. placebo	0.91	0.81–1.02
			SGLT-2 inhibitors vs. GLP-1 RAs	0.71	0.58–0.89
GLP-1 analogues	20088	4357	SGLT-2 inhibitors vs. placebo	0.68	0.59–0.78	0	0.94
			GLP-1 RAs vs. placebo	0.82	0.66–1.01
			SGLT-2 inhibitors vs. GLP-1 RAs	0.83	0.65–1.07

SGLT2i sodium-glucose cotransporter-2 inhibitors, GLP-1 RAs glucagon-like peptide-1 receptor agonists, CI confidence intervals, MACE-3 3-point major adverse cardiovascular event, vs. versus, N/A not available

Back to article page

ISSN: 1475-2840

Contact us

Submission enquiries: journalsubmissions@springernature.com